Trials / Completed
CompletedNCT06728644
The Role of L-arginine in Polycystic Ovary Syndrome
The Safety and Efficacy of L-arginine in Patients With Polycystic Ovary Syndrome
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Shanghai 10th People's Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
PCOS patients meeting the trial criteria were enrolled from the Shanghai 10th People's Hospital. The contents of this study were introduced to them, and they were invited to participate in the study. We further evaluated the efficacy and safety of arginine in treating PCOS by implementing the L-arginine clinical intervention protocol, and conducting post-intervention follow-up, efficacy evaluation, laboratory tests, and fecal sample 16S rRNA sequencing.
Detailed description
In this study, we will enroll PCOS patients who meet the trial criteria from the Shanghai 10th People's Hospital, introduce the content of this study to them, and invite them to participate in the study. Perform laboratory tests for PCOS and collect baseline stool and blood samples. The clinical intervention program of L-arginine was implemented, and post-intervention follow-up, efficacy evaluation and laboratory examination were carried out. Stool and blood samples were collected after the intervention, and 16S rRNA sequencing was performed on stool samples before and after the intervention. To analyze whether PCOS-related clinical and laboratory indicators improved after L-arginine treatment of PCOS, and to analyze the changes in patients' microbiome before and after L-arginine treatment, to clarify the effectiveness and safety of L-arginine treatment of PCOS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | L-arginine intervention | L-arginine intervention for 3 months, 3 g per day. |
Timeline
- Start date
- 2024-07-14
- Primary completion
- 2025-07-04
- Completion
- 2025-07-04
- First posted
- 2024-12-11
- Last updated
- 2025-07-11
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06728644. Inclusion in this directory is not an endorsement.